Affordable Access

deepdyve-link
Publisher Website

Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden.

Authors
  • Kazerouni, Neda J1
  • Irwin, Adriane N1
  • Levander, Ximena A2
  • Geddes, Jonah1
  • Johnston, Kirbee1
  • Gostanian, Carly J1
  • Mayfield, Baylee S1
  • Montgomery, Brandon T1
  • Graalum, Diana C3
  • Hartung, Daniel M4
  • 1 College of Pharmacy, Oregon State University/Oregon Health & Science University, Portland, OR, United States. , (United States)
  • 2 Oregon Health & Science University, Department of Medicine Division of General Internal Medicine Section of Addiction Medicine, 3181 SW Sam Jackson Park Rd., Portland, OR, 97239, United States. Electronic address: [email protected] , (United States)
  • 3 MedSavvy/Cambia Health Solutions, Portland, OR, United States. , (United States)
  • 4 College of Pharmacy, Oregon State University/Oregon Health & Science University, Portland, OR, United States. Electronic address: [email protected] , (United States)
Type
Published Article
Journal
Drug and alcohol dependence
Publication Date
Jul 01, 2021
Volume
224
Pages
108729–108729
Identifiers
DOI: 10.1016/j.drugalcdep.2021.108729
PMID: 33932744
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Pharmacies sometimes restrict access to buprenorphine-naloxone (buprenorphine) for individuals with opioid use disorder. The objective of this study was to quantify the frequency of barriers encountered by patients seeking to fill buprenorphine prescriptions from pharmacies in United States (US) counties with high opioid-related mortality. To characterize buprenorphine availability, we conducted a telephone audit ("secret shopper") study using a standardized script in two randomly selected pharmacies (one chain, one independent) in US counties reporting higher than average opioid overdose rates. Availability across pharmacy type (chain versus independent), county characteristics (rurality, region, overdose rate), and day of week were analyzed using univariate tests of categorical data. Independent predictors of buprenorphine availability were then identified using a multivariable binomial regression model. Among 921 pharmacies contacted (467 chain, 454 independent), 73 % were in urban counties and 42 % were in Southern states. Of these pharmacies, 675 (73 %) reported being able to dispense buprenorphine. There were 183 (20 %) pharmacies that indicated they would not dispense buprenorphine. Independent pharmacies (adjusted prevalence ratio [aPR], 1.59; 95 % CI 1.21-2.08) and pharmacies in Southern states (aPR 2.06; 95 % CI 1.43-2.97) were significantly more likely to restrict buprenorphine. In US counties with high overdose mortality rates, one in five pharmacies indicated they would not dispense buprenorphine. Buprenorphine access limitations were more common among independent pharmacies and those in Southern states. Pharmacy-directed interventions may be necessary to ensure timely buprenorphine access for patients with opioid use disorder. Copyright © 2021 Elsevier B.V. All rights reserved.

Report this publication

Statistics

Seen <100 times